Showing 40,021 - 40,040 results of 65,898 for search '(( 5 nn decrease ) OR ( 5 ((((we decrease) OR (a decrease))) OR (mean decrease)) ))', query time: 1.19s Refine Results
  1. 40021
  2. 40022
  3. 40023
  4. 40024

    DataSheet2_Necroptotic kinases are involved in the reduction of depression-induced astrocytes and fluoxetine’s inhibitory effects on necroptotic kinases.DOCX by Salman Zeb (12897155)

    Published 2023
    “…Here, in a chronic unpredictable mild stress (CUMS) mouse model and a corticosterone (Cort)-induced human astrocyte injury model in vitro, we found that mice treated with chronic unpredictable mild stress for 3–5 weeks presented depressive-like behaviors and reduced body weight gain, accompanied by a reduction in astrocytes and a decrease in astrocytic brain-derived neurotropic factors (BDNF), by activation of necroptotic kinases, including RIPK1 (receptor-interacting protein kinase 1)/p-RIPK1, RIPK3 (receptor-interacting protein kinase 3)/p-RIPK3 and MLKL (mixed lineage kinase domain-like protein)/p-MLKL, and by upregulation of inflammatory cytokines in astrocytes of the mouse hippocampus. …”
  5. 40025

    DataSheet1_Necroptotic kinases are involved in the reduction of depression-induced astrocytes and fluoxetine’s inhibitory effects on necroptotic kinases.pdf by Salman Zeb (12897155)

    Published 2023
    “…Here, in a chronic unpredictable mild stress (CUMS) mouse model and a corticosterone (Cort)-induced human astrocyte injury model in vitro, we found that mice treated with chronic unpredictable mild stress for 3–5 weeks presented depressive-like behaviors and reduced body weight gain, accompanied by a reduction in astrocytes and a decrease in astrocytic brain-derived neurotropic factors (BDNF), by activation of necroptotic kinases, including RIPK1 (receptor-interacting protein kinase 1)/p-RIPK1, RIPK3 (receptor-interacting protein kinase 3)/p-RIPK3 and MLKL (mixed lineage kinase domain-like protein)/p-MLKL, and by upregulation of inflammatory cytokines in astrocytes of the mouse hippocampus. …”
  6. 40026

    Supplementary material for “Genetic insights into causal effects of serum lipids and lipid-lowering drug target genes on autoimmune thyroid disease” by Qinnan Zhang (18874897)

    Published 2024
    “…SMR analysis also showed that APOB expression in subcutaneous adipose tissue is linked to a higher risk of autoimmune thyroiditis. In addition, we also found other target genes had suggestive correlation with autoimmune thyroiditis, such as ANGPTL3 (OR=5.26,95%CI=1.54-17.94; P=0.008), LPL (OR=2.15,95%CI=1.31-3.53; P=0.003) and CETP (OR=0.10,95%CI=0.02-0.48; P=0.005). …”
  7. 40027
  8. 40028

    Table 1_Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis.xlsx by Lu Cheng (141959)

    Published 2025
    “…The correlation of specific intact N-glycopeptides with the clinical features of SSc patients was analyzed. The results revealed a notable increase in the levels of 6 intact N-glycopeptides (IgG2-N3H3F1, IgG2-N3H4F1, IgG2-N4H4F1, IgG2-N4H5F1, IgG2-N5H4F1, and IgG2-N5H5F1) and a decrease in the levels of another set of 6 intact N-glycopeptides (IgG1-N4H3F1, IgG2-N3H6F1A1, IgG2-N4H4F1A1, IgG2-N5H3F1, IgG3-N4H3F1, and IgG3-N4H4F1). …”
  9. 40029

    Table 2_Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis.xlsx by Lu Cheng (141959)

    Published 2025
    “…The correlation of specific intact N-glycopeptides with the clinical features of SSc patients was analyzed. The results revealed a notable increase in the levels of 6 intact N-glycopeptides (IgG2-N3H3F1, IgG2-N3H4F1, IgG2-N4H4F1, IgG2-N4H5F1, IgG2-N5H4F1, and IgG2-N5H5F1) and a decrease in the levels of another set of 6 intact N-glycopeptides (IgG1-N4H3F1, IgG2-N3H6F1A1, IgG2-N4H4F1A1, IgG2-N5H3F1, IgG3-N4H3F1, and IgG3-N4H4F1). …”
  10. 40030

    Table 4_Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis.xlsx by Lu Cheng (141959)

    Published 2025
    “…The correlation of specific intact N-glycopeptides with the clinical features of SSc patients was analyzed. The results revealed a notable increase in the levels of 6 intact N-glycopeptides (IgG2-N3H3F1, IgG2-N3H4F1, IgG2-N4H4F1, IgG2-N4H5F1, IgG2-N5H4F1, and IgG2-N5H5F1) and a decrease in the levels of another set of 6 intact N-glycopeptides (IgG1-N4H3F1, IgG2-N3H6F1A1, IgG2-N4H4F1A1, IgG2-N5H3F1, IgG3-N4H3F1, and IgG3-N4H4F1). …”
  11. 40031

    Data Sheet 1_Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis.doc by Lu Cheng (141959)

    Published 2025
    “…The correlation of specific intact N-glycopeptides with the clinical features of SSc patients was analyzed. The results revealed a notable increase in the levels of 6 intact N-glycopeptides (IgG2-N3H3F1, IgG2-N3H4F1, IgG2-N4H4F1, IgG2-N4H5F1, IgG2-N5H4F1, and IgG2-N5H5F1) and a decrease in the levels of another set of 6 intact N-glycopeptides (IgG1-N4H3F1, IgG2-N3H6F1A1, IgG2-N4H4F1A1, IgG2-N5H3F1, IgG3-N4H3F1, and IgG3-N4H4F1). …”
  12. 40032

    Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib by Gianluigi Giannelli (94866)

    Published 2020
    “…In AFP responders (21% of patients in Part A with decrease of >20% from baseline) versus non-responders, median OS was 21.5 months versus 6.8 months (p = 0.0015). …”
  13. 40033

    Table 3_Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis.xlsx by Lu Cheng (141959)

    Published 2025
    “…The correlation of specific intact N-glycopeptides with the clinical features of SSc patients was analyzed. The results revealed a notable increase in the levels of 6 intact N-glycopeptides (IgG2-N3H3F1, IgG2-N3H4F1, IgG2-N4H4F1, IgG2-N4H5F1, IgG2-N5H4F1, and IgG2-N5H5F1) and a decrease in the levels of another set of 6 intact N-glycopeptides (IgG1-N4H3F1, IgG2-N3H6F1A1, IgG2-N4H4F1A1, IgG2-N5H3F1, IgG3-N4H3F1, and IgG3-N4H4F1). …”
  14. 40034

    Table_1_Dual RNA-seq in filarial nematodes and Wolbachia endosymbionts using RNase H based ribosomal RNA depletion.XLSX by Lindsey J. Cantin (18582037)

    Published 2024
    “…We compared the total RNA library to poly-A enriched, Terminator 5′-Phosphate-Dependent Exonuclease treated, NEBNext Human/Bacteria rRNA depleted and our custom nematode probe depleted libraries. …”
  15. 40035

    Presentation_1_Dual RNA-seq in filarial nematodes and Wolbachia endosymbionts using RNase H based ribosomal RNA depletion.PPTX by Lindsey J. Cantin (18582037)

    Published 2024
    “…We compared the total RNA library to poly-A enriched, Terminator 5′-Phosphate-Dependent Exonuclease treated, NEBNext Human/Bacteria rRNA depleted and our custom nematode probe depleted libraries. …”
  16. 40036

    Table_2_Dual RNA-seq in filarial nematodes and Wolbachia endosymbionts using RNase H based ribosomal RNA depletion.XLSX by Lindsey J. Cantin (18582037)

    Published 2024
    “…We compared the total RNA library to poly-A enriched, Terminator 5′-Phosphate-Dependent Exonuclease treated, NEBNext Human/Bacteria rRNA depleted and our custom nematode probe depleted libraries. …”
  17. 40037
  18. 40038

    Intestinal overexpression of <i>mir-2</i> enhances DA neurodegeneration and is attenuated by AIM-100 when <i>sid-1</i> is wildtype. by Anthony L. Gaeta (13272609)

    Published 2022
    “…(<b>G</b>) DA neurons were scored for degeneration on days 5 and 7 post-hatching. Values represent mean <u>+</u> S.D. …”
  19. 40039

    Synaptotoxic PrP<sup>Sc</sup> species are propagated from early in the evolution of M1000 prion disease. by Simote Totauhelotu Foliaki (5614364)

    Published 2019
    “…<p>(A) CA1 region LTP of WT mouse hippocampal slices was significantly disrupted following a five minute exposure to 0.5% (w/v; in artificial CSF) crude M1000 brain homogenates (cM1000) derived from M1000 infected WT Balb/c mice (infected through routine intracerebral injection [R.ic]) at 30% of the incubation period to the terminal stage of disease (TSD). …”
  20. 40040

    Can Forest Management Practices Counteract Species Loss Arising from Increasing European Demand for Forest Biomass under Climate Mitigation Scenarios? by Francesca Rosa (3509216)

    Published 2023
    “…This outcome stems from a projected increase in EU forest biomass imports, partially from biodiversity-vulnerable regions to compensate for a decrease in domestic harvest. …”